The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix (Q40391633)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

20 September 2017

The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix (English)

1 reference

Europe PubMed Central

20 September 2017

Listeria monocytogenes

0 references

0 references

attenuated vaccine

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Paulo Cesar Maciag

1

object named as

Paulo Cesar Maciag

1 reference

Europe PubMed Central

20 September 2017

author name string

Paulo Cesar Maciag

1

1 reference

Europe PubMed Central

20 September 2017

Sinisa Radulovic

2

1 reference

Europe PubMed Central

20 September 2017

John Rothman

3

1 reference

Europe PubMed Central

20 September 2017

language of work or name

0 references

publication date

3 May 2009

1 reference

Europe PubMed Central

20 September 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

20 September 2017

27

1 reference

Europe PubMed Central

20 September 2017

30

1 reference

Europe PubMed Central

20 September 2017

3975-3983

1 reference

Europe PubMed Central

20 September 2017

Global cancer statistics in the year 2000.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Initial lessons learned in HPV vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Therapeutic human papillomavirus vaccines: current clinical trials and future directions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Foodborne listeriosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Listeriolysin O: a phagosome-specific lysin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Immune responses to Listeria monocytogenes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Development of a Listeria monocytogenes based vaccine against prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors im

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Listeria monocytogenes-based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Gastroenteritis due to Listeria monocytogenes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Circulating cytokines as mediators of fever

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Macrophages of the splenic marginal zone are essential for trapping of blood-borne particulate antigen but dispensable for induction of specific T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Cisplatin nephrotoxicity: mechanisms and renoprotective strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Carboplatin versus cisplatin in solid tumors: an analysis of the literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Comparative adverse effect profiles of platinum drugs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Combined modality immunotherapy and chemotherapy: a new perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Therapeutic vaccination for HPV induced cervical cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.041

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.04.041

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40391633&oldid=1896764140"